NasdaqGS:PODDMedical Equipment
Insulet’s Omnipod 5 Win for Type 2 Diabetes Reshapes Growth Outlook
Insulet received FDA clearance for its Omnipod 5 insulin delivery system for people with type 2 diabetes, expanding beyond its existing type 1 use.
The company also won a trade secret legal case against EOFlow, supporting protection of its insulin pump technology.
These updates arrive as Insulet (NasdaqGS:PODD) trades around $251.24 per share.
For investors watching Insulet (NasdaqGS:PODD), these developments come after a period of weaker share performance, with the stock showing declines...